Panel discussions
In this panel discussion Citeline and leading European investors will discuss the latest trends that are shaping venture capital deployment in innovative biotech start-ups both in Switzerland and beyond. With recent years seeing investment concentrated in fewer companies with larger raises, are VCs broadening their focus? Increasing competition in high-activity therapeutic areas and technologies leaves less room to add value but remains a core focus for potential pharma partners. This session will help biotech leaders stay ahead of market dynamics and hone their deal-making pitch.
May 5, 14:30 - 15:15, room Marriott 3+4+5
| Name | Position | Institution |
|---|---|---|
| Kevin Grogan | Managing Editor Europe, Commercial | Scrip |
| Name | Position | Institution |
|---|---|---|
| Anta Gkelou | Partner | Sofinnova Capital Strategy |
Citeline (a Norstella company) powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth.
